+34 620 10 75 37info@nanbiosis.com

News

nanbiosis news

Dr.Ramón Martínez Máñez has been appointed Scientific Director of the CIBER-BBN

Dr. Ramon Martinez Máñez, CIBER-BBN researcher at the Polytechnic University of Valencia, has been appointed Scientific Director of the CIBER-BBN in the CIBER Standing Committee of the Institute of Health Carlos III. Martinez-Máñez relieves Dr. Pablo Laguna, who occupied this position since February 2011.

Ramon Martinez Máñez is Principal Investigator of CIBER-BBN in the Group of Applied Molecular Chemistry Center of Molecular Recognition and Technological Development of the Polytechnic University of Valencia (UPV-ADM-IQMA).

“Some of the challenges and objectives in this new stage will be the promotion of competitiveness and quality of research, promote collaboration between groups both in the CIBER-BBN as other CIBER groups and promoting translational research, especially for clinical applications, “said Ramon Martinez Máñez.

The CIBER-BBN consists of 46 research groups, selected on the basis of scientific excellence, working mainly in three scientific programs: bioengineering and medical imaging; biomaterials and advanced therapies; and nanomedicine.

Martinez Máñez coordinator of BIOGATES, Intramural CIBER-BBN project, investigating new nanoparticles for diagnostics and drug delivery. The research group lines also fall within the Scientific Nanomedicine CIBER-BBN Program. This research group works with other CIBER-BBN groups in the development of nanoscale devices “molecular gates” for controlled drug release. Mesoporous silica nanoparticles with which they work are able to hold a charge in its pore system and deliver it when they applied a chemical, physical or biochemical stimulus. Other applications of these nanoparticles has been the selective delivery of cytotoxic for cancer cells, removal of bacteria or the release of certain drugs in senescent cells. Another of his lines of work is the development of probes for the detection of molecules of biological interest.

BBN_MARTINEZMANEZ
Read More

JUMISC works in a R&D project: Stem cell therapy for cartilage repair

The Jesús Usón Minimally Invasive Surgery Centre (JUMISC) works in a R&D project, that aims to find a biomaterial that will help injured cartilage to repair.

The targets of the project are to design a biomaterial that could be implanted in the human body and to apply it in the osteoarticular pathology treatment. The main goal is that people who suffer from osteoarthritis, a pathology that damages the cartilage joint, get better through a minimally invasive surgery procedure.

The consecutive phases of the project will be the development of the biomaterial, tests in vitro and the preclinical trials, as testing in pig animal model.

After finishing these phases, vet professionals will monitore them, through imaging and surgery techniques, using MRI scan and arthroscopy, to study the evolution of the injuries.

At the end of the R&D project, those injured joints where the biomaterial was implanted, will be analyzed through microscopy techniques, and vet professionals will determine if the cartilage has improved.

JUMISC and the partners of the project (enterprises, hospitals and others) are focused on testing that the treatment is safe and effective, and from this premise we will be ready to start clinical trials in hospitals, in order to demonstrate the effectiveness of the biomaterial in patients.

JUMISC- Arthroscopy -Stem cell therapy for cartilage repair
Read More